$CDNA earnings report

Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million. AlphAI read CareDx's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readCDNA · Third Quarter 2026 · ended September 30, 2026

Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million

✓Strong quarter

Revenue increased 39% year-over-year to $139 million, Testing Services revenue increased 65%, GAAP net income was $19 million versus $2 million, adjusted EBITDA was $30 million versus $15 million, and the company raised both full-year revenue and Adjusted EBITDA guidance.

Revenue
$139M
39% y/y
Testing Services
$119M
65% y/y
Gross margin · GAAP
71 %
EPS · non-GAAP
$ 0.70
Full year 2026 outlook
$520 million to $530 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$139.4M–39%
Testing services revenueGAAP$119.2M–65%
Product revenueGAAP$ —––
Patient and digital solutions revenueGAAP$20.17M–31%
Testing Services volumeotherapproximately 75,900–51%
Testing Services revenue excluding revenue recognized for tests performed in prior periodsGAAP:null–approximately 58%
Testing Services revenue from tests performed in prior periodsGAAP$15M––
Specialty Oncology revenueGAAP$12M––
Cost of testing servicesGAAP$24.68M––
Cost of productGAAP$ —––
Cost of patient and digital solutionsGAAP$15.60M––
GAAP cost of salesGAAP40,287––
GAAP gross profitGAAP$99.08M––
GAAP gross marginGAAP71 %––
Non-GAAP gross profitnon-GAAP$102.5M––
Non-GAAP gross marginnon-GAAP74 %––
Research and developmentGAAP$21.32M––
Sales and marketingGAAP$31.65M––
General and administrativeGAAP$37.99M––
Total GAAP operating expensesGAAP$90.96M––
Total operating expensesGAAP131,250––
Non-GAAP research and development expensesnon-GAAP$20.13M––
Non-GAAP sales and marketing expensesnon-GAAP$30.00M––
Non-GAAP general and administrative expensesnon-GAAP$25.14M––
Total Non-GAAP operating expensesnon-GAAP$75.27M––
Income (loss) from operationsGAAP8,112––
Interest income, netGAAP2,208––
Other income (expense), netGAAP372––
Total other incomeGAAP2,580––
Income before income taxesGAAP10,692––
Income tax benefitGAAP8,600––
GAAP net incomeGAAP$19.29M––
GAAP net income marginGAAP14 %––
GAAP basic net income per shareGAAP$ 0.37––
GAAP diluted net income per shareGAAP$ 0.35––
Non-GAAP net incomenon-GAAP$38.37M––
Non-GAAP basic net income per sharenon-GAAP$ 0.74––
Non-GAAP diluted net income per sharenon-GAAP$ 0.70––
Adjusted EBITDAnon-GAAP$30.50M––
Adjusted EBITDA marginnon-GAAP22 %––
Net cash provided by operating activitiesGAAP$12.72M––
Capital expendituresGAAP−$1.61M––
Free cash flownon-GAAP$11.10M––

Segments

SegmentRevenueq/qy/y
Testing ServicesGrowth included $12 million in Specialty Oncology revenue and contributions following the acquisition of NavDx; Testing Services revenue also included $15 million in prior period revenue.$119M–65%
Patient and Digital SolutionsDriven primarily by continued growth in CareDx Pharmacy services.$20M–31%
Lab ProductsThe Company completed the divestiture of its Lab Products business on June 30, 2026, and third quarter 2026 results do not include Lab Products revenue.$ —––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$520 million to $530 million
  • NoteAdjusted EBITDA of $90 million to $100 million
  • NotePreviously disclosed revenue range of $490 million to $500 million
  • NotePreviously disclosed Adjusted EBITDA range of $66 million to $78 million

What drove it

  • Testing Services revenue increased 65% year-over-year, including $12 million in Specialty Oncology revenue.
  • Testing Services volume increased 51% year-over-year, including contributions from Specialty Oncology.
  • Patient and Digital Solutions revenue growth was driven primarily by continued growth in CareDx Pharmacy services.
  • Adjusted EBITDA was driven by revenue growth, higher gross profit and disciplined operating expense management.
  • The Company closed the acquisition of Naveris, Inc. on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration.
  • The Company advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027.

Concerns

  • Testing Services revenue included $15 million in prior period revenue, compared with $6 million in the third quarter of 2025.
  • GAAP gross margin was 71 %, compared with 74 % in the three months ended June 30, 2026.
  • Net cash provided by operating activities was $ 12,718, compared with $ 37,358 in the third quarter of 2025.
  • The Company recorded $ 5,527 of business development and portfolio optimization expense, primarily related to the sale of its Lab Products business and acquisition of Naveris, Inc.
  • The Company completed the divestiture of its Lab Products business on June 30, 2026; third quarter 2026 results do not include Lab Products revenue.

What to watch

  • Execution toward the planned first-quarter 2027 commercial launch of AlloHeme and broader commercial availability of HistoMap Kidney in 2027.
  • Testing Services volume and the contribution from Specialty Oncology following the acquisition of NavDx.
  • The magnitude of revenue recognized for tests performed in prior periods.
  • CareDx Pharmacy services growth within Patient and Digital Solutions.
  • Migration of NavDx to the CareDx billing platform and continued Epic Aura adoption.
  • Delivery against full-year 2026 revenue guidance of $520 million to $530 million and Adjusted EBITDA guidance of $90 million to $100 million.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 250,480 as of September 30, 2026, compared with $ 65,429 as of December 31, 2025.
  • Marketable securities were $ — current and $ — non-current as of September 30, 2026, compared with $ 111,779 current and $ 24,165 non-current as of December 31, 2025.
  • Total assets were $ 641,457 as of September 30, 2026, compared with $ 413,228 as of December 31, 2025.
  • Total liabilities were 174,001 as of September 30, 2026, compared with 110,127 as of December 31, 2025.
  • Contingent consideration, non-current was 14,035 as of September 30, 2026, compared with 161 as of December 31, 2025.
  • Total stockholders’ equity was 467,456 as of September 30, 2026, compared with 303,101 as of December 31, 2025.
  • Net cash provided by operating activities was $ 12,718, capital expenditures were $ (1,615), and free cash flow was $ 11,103 for the three months ended September 30, 2026.

Analysis

CareDx reported third-quarter total revenue of $139 million, up 39% year-over-year from $100 million. Testing Services revenue was $119 million, up 65% year-over-year, while Patient and Digital Solutions revenue was $20 million, up 31%. Testing Services volume increased 51% year-over-year to approximately 75,900. The revenue mix included $12 million in Specialty Oncology revenue and $15 million in Testing Services revenue recognized for tests performed in prior periods.

Profitability improved substantially year-over-year. GAAP net income was $19 million, compared with $2 million, and GAAP diluted net income per share was $0.35, compared with $0.03. Adjusted EBITDA was $30 million, compared with $15 million, with adjusted EBITDA margin of approximately 22%, compared with approximately 15%. GAAP gross margin was 71%, compared with 69% in the third quarter of 2025, while non-GAAP gross margin was 74%, compared with 71%.

Sequentially, GAAP total revenue was $139,362, compared with $131,948 in the three months ended June 30, 2026. GAAP gross margin was 71%, compared with 74%, while adjusted EBITDA increased to $30,496 from $24,804 and adjusted EBITDA margin increased to 22% from 19%. GAAP net income for the June quarter was $110,636 and included a $112,966 gain on sale of the Lab Products business in the adjusted EBITDA reconciliation.

The balance sheet reflected $250,480 of cash and cash equivalents at September 30, 2026, versus $65,429 at December 31, 2025. The company closed the Naveris acquisition on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration. Third-quarter net cash provided by operating activities was $12,718 and free cash flow was $11,103.

Management raised full-year 2026 revenue guidance to $520 million to $530 million from $490 million to $500 million and raised Adjusted EBITDA guidance to $90 million to $100 million from $66 million to $78 million. The operational focus includes the planned first-quarter 2027 commercial launch of AlloHeme, broader HistoMap Kidney commercial availability in 2027, scaling Specialty Oncology, and the migration of NavDx to the CareDx billing platform.

Management, verbatim

We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.

John Hanna, President and Chief Executive Officer of CareDx

We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.

John Hanna, President and Chief Executive Officer of CareDx

Not in the filing

stated, not guessed
  • A separate previous-release outlook section was not provided; therefore, no actual-versus-prior-guidance comparison is presented.
  • Debt balances were not reported in the provided balance sheet.
  • Share repurchases and dividends were not reported.
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, GAAP net income, GAAP EPS, operating cash flow and free cash flow was not reported.
  • Prior-year and prior-quarter Testing Services volume figures were not reported.
  • Year-over-year and sequential percentage changes for most statement-of-operations line items were not reported.
  • A numeric value for Testing Services revenue excluding revenue recognized for tests performed in prior periods was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readCDNA · Second Quarter 2026 · ended June 30, 2026

Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million

✓Strong quarter

Revenue grew 52% year-over-year, Testing Services revenue grew 61%, adjusted EBITDA rose to $25 million from $5 million, and the company raised both full-year 2026 revenue and adjusted EBITDA guidance. GAAP net income included a $113 million gain on the Lab Products business sale.

Revenue
$132M
52% y/y
Testing Services
$100M
61% y/y
EPS · non-GAAP
$0.37
Full year 2026 outlook
$490 million to $500 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$132M–52%
Testing Services revenueGAAP$100M–61%
Testing Services volumeotherapproximately 58,000–17%
Testing Services revenue excluding revenue recognized for tests performed in prior periodsGAAPincreased approximately 28% year-over-year–approximately 28%
Average revenue per testotherapproximately $1,720––
Prior period revenue included in average revenue per testother$16M––
Patient and Digital Solutions revenueGAAP$19M–50%
Lab Product revenueGAAP$13M–8%
Net incomeGAAP$111M––
Basic net income per shareGAAP$2.15––
Diluted net income per shareGAAP$2.07––
Non-GAAP net incomenon-GAAP$20M––
Diluted non-GAAP net income per sharenon-GAAP$0.37––
Adjusted EBITDAnon-GAAP$25M––
Gain on sale of Lab Products businessGAAP$113M––
Cash flow from operationsGAAP$31M––

Segments

SegmentRevenueq/qy/y
Testing ServicesOngoing adoption of molecular surveillance testing across transplant programs; revenue growth reflected continued demand across transplant programs, favorable reimbursement dynamics, and increases in testing activity across both surveillance and for-cause settings.$100M–61%
Patient and Digital SolutionsContinued growth in CareDx Pharmacy services and adoption of patient support and digital solutions across transplant monitoring.$19M–50%
Lab ProductThe quarter reflects a full period of Lab Products results. The divestiture to Eurobio Scientific closed on June 30, 2026, and future periods will no longer include Lab Products segment results.$13M–8%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$490 million to $500 million
  • NoteAdjusted EBITDA: $66 million to $78 million

What drove it

  • Higher Testing Services revenue and continued expansion of Patient and Digital Solutions revenue.
  • Continued demand across transplant programs, favorable reimbursement dynamics, and increased testing activity across surveillance and for-cause settings.
  • Strong Testing Services revenue growth, improved gross profit, operational efficiency, and cost discipline supported adjusted EBITDA.
  • CMS finalized Medicare coverage policy for AlloSure® and AlloMap®, supporting continued patient access to molecular testing in transplant care.
  • The company completed the Lab Products divestiture to Eurobio Scientific and closed the acquisition of Naveris.

Concerns

  • Testing Services revenue included $16 million in prior period revenue, while revenue excluding tests performed in prior periods increased approximately 28% year-over-year.
  • GAAP net income and GAAP operating income included a $113 million gain on sale of the Lab Products business, which was excluded from non-GAAP operating income.
  • Future periods will no longer include Lab Products segment results following the June 30, 2026 divestiture.

What to watch

  • Execution on the raised full-year 2026 revenue guidance of $490 million to $500 million and adjusted EBITDA guidance of $66 million to $78 million.
  • Testing Services volume, molecular surveillance adoption, reimbursement dynamics, and testing activity across surveillance and for-cause settings.
  • Integration of Naveris and the planned launch into cell therapy.
  • Progress toward CLIA readiness for AlloHeme® and the evolving clinical evidence for HistoMap®, NavDx®, and AlloSure®.

Balance sheet and cash flow

  • Cash flow from operations of $31 million

Analysis

CareDx reported a strong second quarter, with total revenue of $132 million, up 52% year-over-year from $87 million. Testing Services was the principal growth engine, rising 61% year-over-year to $100 million, while testing services volume increased 17% year-over-year to approximately 58,000. Management attributed growth to transplant-program demand, favorable reimbursement dynamics, and higher testing activity across surveillance and for-cause settings.

Testing Services revenue included $16 million in prior period revenue, and revenue excluding tests performed in prior periods increased approximately 28% year-over-year. Average revenue per test was approximately $1,720. Patient and Digital Solutions revenue increased 50% year-over-year to $19 million, supported by CareDx Pharmacy services and patient support and digital-solution adoption. Lab Product revenue rose 8% year-over-year to $13 million, but this revenue stream will not recur in future periods following the completed divestiture.

Profitability improved materially on a non-GAAP basis. Non-GAAP net income was $20 million versus $6 million in the second quarter of 2025, diluted non-GAAP net income per share was $0.37 versus $0.10, and adjusted EBITDA was $25 million versus $5 million. Management cited Testing Services revenue growth, improved gross profit, operational efficiency, and cost discipline. Cash flow from operations was $31 million.

GAAP profitability was significantly affected by portfolio actions. GAAP net income was $111 million, compared with a GAAP net loss of $9 million, and diluted GAAP net income per share was $2.07 compared with a diluted GAAP net loss per share of $0.16. The sale of the Lab Products business closed on June 30, 2026 and resulted in a $113 million gain included in GAAP operating income and excluded from non-GAAP operating income.

Management raised full-year 2026 revenue guidance to $490 million to $500 million from the previously disclosed $447 million to $465 million range, and raised adjusted EBITDA guidance to $66 million to $78 million from $43 million to $57 million. The operating focus now centers on sustained transplant testing demand, integration of Naveris, the cell-therapy launch, and execution without future Lab Products segment revenue.

Management, verbatim

We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth. Our performance reflects that our strategy is working, and we look forward to building on our momentum as we integrate NavDx and launch into cell therapy.

John Hanna, President and Chief Executive Officer of CareDx

Not in the filing

stated, not guessed
  • Condensed consolidated financial-statement tables were not included in the provided filing text.
  • GAAP gross profit, GAAP gross margin, non-GAAP gross profit, and non-GAAP gross margin.
  • GAAP operating income excluding the disclosed $113 million gain on sale of the Lab Products business.
  • Non-GAAP operating income.
  • Operating expenses and expense-line-item detail.
  • Cash balance, debt balance, and other balance-sheet amounts.
  • Capital expenditures and corporate free cash flow.
  • Share repurchases, dividends, and other capital-return amounts.
  • Prior-quarter comparisons for revenue, segments, earnings, EPS, adjusted EBITDA, testing volume, and cash flow from operations.
  • Forward guidance for gross margin, operating expenses, tax rate, cash flow, capital expenditures, or free cash flow.
  • A separately provided previous-release outlook required for vs_prior_guidance comparisons.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CDNA earnings dates

When is CareDx's next earnings date?
AlphAI has no date for CDNA yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.